Fluoroquinolone antibiotics

Study: Common Drugs Associated with Increased Risk for Cardiac Arrhythmia and Sudden Death in Elderly Patients

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Chemical compounds, Organic compounds, Tertiary alcohols, Fluoroquinolone antibiotics, Enantiopure drugs, Macrolide antibiotics, Otologicals, Fluconazole, Erythromycin, Ofloxacin, Amoxicillin

This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.

Key Points: 
  • This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.
  • Of the short-term drugs, researchers found the antibiotics levofloxacin increased the risk of cardiac arrhythmia or sudden death by 51% compared to the amoxicillin control, while erythromycin had an increased risk of 63%.
  • The anti-nausea drug ondansetron increased the risk of a cardiac adverse event by 205%, while the antifungal fluconazole increased the risk by 123%.
  • Current patients prescribed the antipsychotics showed an increased risk of arrhythmia or sudden death of 118% compared to patients who never received the drug.

China Moxifloxacin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Health, Pharmaceutical, Chemical compounds, Fluoroquinolone antibiotics, Cyclopropanes, Moxifloxacin, Drugs

Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis.

Key Points: 
  • Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis.
  • The survey data shows that the sales value of Moxifloxacin has grown steadily from 2016 to 2019 in China.
  • Moxifloxacin of Bayer Vital GmbH dropped by 77.70%, and Moxifloxacin of Nanjing Youke Pharmaceutical Co., Ltd. dropped by 53.07%.
  • 2 Sales of Moxifloxacin in China, 2016-2020
    2.3 Sales of Moxifloxacin by Dosage Form in China, 2016-2020

Investigation Report on China's Levofloxacin Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021
Infectious diseases, Pharmaceutical, Health, Drugs, Fluoroquinolone antibiotics, Health sciences, Health care, Enantiopure drugs, Janssen Pharmaceutica, Levofloxacin, Sanofi, Daiichi Sankyo, Ofloxacin, Economy of China, Pharmaceutical industry

The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Levofloxacin Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Levofloxacin tablets were approved in China in 1995, and Levofloxacin injection and oral regular-release liquids have entered China's medical insurance.
  • By the half-past of 2021, there are many manufacturers in China's Levofloxacin market, among which Daiichi Sankyo Pharmaceutical (Beijing) accounts for the highest proportion of market share.
  • According to the market research, the sales value of Levofloxacin in the Chinese market from 2016 to 2019 has shown an overall upward trend.

Author of Perilous Pills Warns Public About Fluoroquinolone Antibiotic Harm

Retrieved on: 
Wednesday, June 16, 2021
Drugs, Chemical compounds, Fluoroquinolone antibiotics, Health care, Quinolone antibiotic, Levofloxacin, Moxifloxacin, Ciprofloxacin, Ofloxacin, Antibiotic, Heise, Opioid

EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.

Key Points: 
  • EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.
  • Heise started investigating and discovered hundreds of thousands had been harmed by these drugs, which include Cipro and Avelox.
  • Extensive research resulted in a book called Perilous Pills, Protecting Yourself from Fluoroquinolone Injury .
  • Much more attention and research are needed, according to the author.

ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients

Retrieved on: 
Thursday, June 3, 2021
Drugs, Health, Fluoroquinolone antibiotics, Otologicals, Microbiology, Scottish inventions, Secondary metabolites, Otitis media, Ciprofloxacin, Otitis, Ofloxacin, Penicillin

Additionally, ALK will also now offer our other allergy immunotherapy products and penicillin allergy testing to an expanded set of healthcare provider specialties."

Key Points: 
  • Additionally, ALK will also now offer our other allergy immunotherapy products and penicillin allergy testing to an expanded set of healthcare provider specialties."
  • OTIPRIO is a sterile, preservative-free, otic suspension of 6 percent ciprofloxacin administered as a single-dose by a healthcare professional.
  • For AOE, OTIPRIO is administered as a single 0.2 mL (12 mg) administration to the external ear canal of each affected ear.
  • The tubes are placed for the treatment of persistent or recurrent otitis media (infection and/or inflammation of the middle ear).

MerLion Pharmaceuticals Completes Growth Financing Round

Retrieved on: 
Tuesday, May 18, 2021
Fluoroquinolone antibiotics, Chemical compounds, Drugs, Chemistry, Cyclopropanes, Finafloxacin, Nitriles, Otologicals, Ofloxacin, Quinolone antibiotic, Otitis externa, Merlion

\xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.

Key Points: 
  • \xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.
  • Its superior, fast acting properties will aid patients considerably in their recovery.\xe2\x80\x9d\nMerLion Pharmaceuticals GmbH is a is a privately held company biopharmaceutical company headquartered in Berlin, Germany.
  • MerLion is supported by a group of leading global investors.
  • For more information, please visit http://www.merlionpharma.com\nPOELLATH, Munich, Dr. Michael Inhester and Adalbert Makos advised MerLion on the investment and capital raise.\nFinafloxacin is a novel fluoroquinolone antibiotic with best-in-class features.

Global Urinary Tract Infections Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, General Health, Medical specialties, Clinical medicine, Medicine, Infectious diseases, Epidemiology, Urinary tract infection, Infection, Enterobacteriaceae, Fluoroquinolone antibiotics, Healthcare-associated infections, Urinary incontinence, Pyelonephritis

b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Urinary Tract Infections Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Urinary Tract Infections Epidemiology and Patient Flow Analysis - 2021, provides Urinary Tract Infections epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Urinary Tract Infections patients, history of the disease at the population level (Urinary Tract Infections prevalence, Urinary Tract Infections incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nUrinary Tract Infections patient flow: Urinary Tract Infections prevalence, diagnosed, and drug-treated patients\nDemographics: Urinary Tract Infections patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Urinary Tract Infections market sizing, assessing market potential, and developing drug forecast models\nIdentify Urinary Tract Infections patients segments through age groups, gender, and disease sub-types\nEvaluate Urinary Tract Infections market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005206/en/\n'

New Report by World Animal Protection Documents Antibiotic Resistance in the Environment Near US Factory Farms

Retrieved on: 
Monday, April 19, 2021
Articles, Health sciences, Health, Fluoroquinolone antibiotics, Livestock, Meat industry, Evolutionary biology, Pharmaceuticals policy, Ofloxacin, Quinolone antibiotic, Cephalosporin, Intensive animal farming

However, the high density of pig and poultry farms in the area means that upstream sample sites may be regularly impacted by discharges from farms further upstream.\n"The implications of antibiotic resistance throughout the environment near large factory farms are extremely concerning," says Cameron Harsh, Farming Campaign Manager, World Animal Protection US.

Key Points: 
  • However, the high density of pig and poultry farms in the area means that upstream sample sites may be regularly impacted by discharges from farms further upstream.\n"The implications of antibiotic resistance throughout the environment near large factory farms are extremely concerning," says Cameron Harsh, Farming Campaign Manager, World Animal Protection US.
  • "\nThe new report reveals very wide evidence of ARGs conveying resistance to streptomycin, fluoroquinolones, cephalosporins, macrolides, and mostbroadly, tetracycline.
  • Their prevalence near swine farms has been previously reported, and the World Health Organization (WHO) identifies them as a global threat.
  • ARGs conveying resistance to important medicines were identified in all countries, including resistance to cephalosporins and fluoroquinolones.

Animal Antibiotics and Antimicrobials Market worth $5.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 8, 2021
Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Fluoroquinolone antibiotics, Quinolone antibiotic, Antimicrobial, Antibiotic, Ofloxacin, Sulfonamide

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.

Key Points: 
  • Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.
  • In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market.
  • Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals.
  • The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Animal Antibiotics and Antimicrobials Market worth $5.6 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 8, 2021
Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Fluoroquinolone antibiotics, Quinolone antibiotic, Antimicrobial, Antibiotic, Ofloxacin, Sulfonamide

Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.

Key Points: 
  • Based on products, the global animal antimicrobials and antibiotics market is segmented into tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobial and antibiotic products.
  • In 2020, the premixes segment accounted for the largest share of 46.3% of the global animal antibiotics market.
  • Based on animal type, the global animal antimicrobials and antibiotics market is categorized into food-producing animals and companion animals.
  • The animal antimicrobials and antibiotics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.